11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
22 Jul
BAVA
Er der rigtigt forstået, at vi venter på at flere i forsøget skal dø før vi kan se på resultatet?   ..
51
21 Jul
FING-B
Du er overalt. Du skriver i Fingersprint trådene og opretter derefter ny tråd med samme indhold. Nu ..
45
23 Jul
BAVA
Spændende og meget relevante spørgsmål Pits.   Vi har indtil nu nået de første to analysetidspunkte..
25
19 Jul
GEN
Ja, det ligner simpelthen ingenting. Siden starten af 2012 er Genmab under ledelse af Jan W. kun ste..
24
25 Jul
FING-B
I dag hvor Finger er under et mindre pres er det vigtigt at man holder fast i sin strategi og spørg ..
21
23 Jul
BAVA
Gode spørgsmål!   Ja, der er en klar sammenhæng mellem tilvalg/fravalg af behandling indenfor prosta..
15
22 Jul
NOVO-B
Stærk analyse.  
14
08:06
PNDORA
Haha du sidder stadig der og skriger ovre i hjørnet.......mens vi andre har nydt ferien....Bliver du..
13
20 Jul
 
Et kæmpe tab. En sindsyg dygtig, højt respekteret og solid klippe af "sund fornuft" som igennem mang..
11
22 Jul
VWS
Bid mærke i, at nu er selv energikæmpen GE mere grøn end sort: http://www.business.dk/energi/groen-e..
10

Alliance Trust PLC : Net Asset Value(s)

26/07/2017 12:50:03
ALLIANCE TRUST PLC                                    At the close of business on Tuesday 25 July 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 759.9p -       including income, 768.5p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding income..

Form 8.5 (EPT/RI) - Tesco plc

26/07/2017 09:43:41
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
ATOS : First half 2017 results
2
Columbia University Medical Center’s Center for Biomedical Informatics Collaborates with Admera Health in a Clinical Study, Evaluating Pharmacogenetics in Psychiatric Medications
3
Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
4
STMicroelectronics Reports 2017 Second Quarter and First Half Financial Results
5
Timberland Bank Reports Growing Profitability for 2017’s Third Fiscal Quarter:

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 July 2017 17:35:02
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170720.2 - EUROWEB6 - 2017-07-26 18:35:02 - 2017-07-26 17:35:02 - 1000 - Website: OKAY